John Overdeck’s AYTU BioPharma AYTU Stock Holding History

John Overdeck’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Sell	105,326 -16,647	-14%	-$39.3K	﹤0.01%	4708
2026 Q1	$333K	Buy	121,973 +14,840	+14%	+$37.9K	﹤0.01%	4006
2025 Q4	$279K	Buy	107,133 +38,397	+56%	+$86.1K	﹤0.01%	3612
2025 Q3	$129K	Buy	68,736 +33,701	+96%	+$77.9K	﹤0.01%	3436
2025 Q2	$76.4K	Buy	+35,035	New	+$54.4K	﹤0.01%	3026
2023 Q1	–	Sell	-746	Closed	-$2.82K	–	2959
2022 Q4	$2.82K	Sell	746 -574	-43%	-$2.16K	﹤0.01%	2762
2022 Q3	$5K	Sell	1,320 -724	-35%	-$5.49K	﹤0.01%	2426
2022 Q2	$28K	Buy	+2,044	New	+$26.2K	﹤0.01%	2381
2020 Q3	–	Sell	-487	Closed	-$138K	–	3070
2020 Q2	$138K	Buy	+487	New	+$147K	﹤0.01%	2740

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

John Overdeck's AYTU Position: Q2 2026 in Review

John Overdeck reduced its AYTU BioPharma (AYTU) stake by 14% in Q2 2026, selling an estimated $39.3K and leaving 105,326 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #4708.

John Overdeck first reported a position in AYTU in Q2 2020 and has held it in 9 quarters since. The position peaked at $333K in Q1 2026. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

John Overdeck held 105,326 shares of AYTU BioPharma worth $226K as of Q2 2026.
John Overdeck sold 16,647 AYTU BioPharma shares in Q2 2026, an estimated $39.3K.
AYTU BioPharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4708 holding.
John Overdeck first reported a position in AYTU BioPharma in Q2 2020 and has held it in 9 quarters since.
John Overdeck's AYTU BioPharma position peaked at $333K in Q1 2026.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.